Ru(II)‐Cyanine Complexes as Promising Photodynamic Photosensitizers for the Treatment of Hypoxic Tumours with Highly Penetrating 770 nm Near‐Infrared Light
Albert Gandioso
(1)
,
Eduardo Izquierdo-García
(1)
,
Pierre Mesdom
(1)
,
Philippe Arnoux
(2)
,
Nurikamal Demeubayeva
(2)
,
Pierre Burckel
(3)
,
Bruno Saubaméa
(4)
,
Manel Bosch
(5)
,
Céline Frochot
(2)
,
Vicente Marchán
(5)
,
Gilles Gasser
(1)
1
ENSCP -
Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL
2 LRGP - Laboratoire Réactions et Génie des Procédés
3 IPGP (UMR_7154) - Institut de Physique du Globe de Paris
4 P-MIM - UMS 3612 - Plates-formes mutualisées du centre de recherche pharmaceutique de Paris
5 UB - Universitat de Barcelona
2 LRGP - Laboratoire Réactions et Génie des Procédés
3 IPGP (UMR_7154) - Institut de Physique du Globe de Paris
4 P-MIM - UMS 3612 - Plates-formes mutualisées du centre de recherche pharmaceutique de Paris
5 UB - Universitat de Barcelona
Albert Gandioso
- Fonction : Auteur
- PersonId : 1276339
Philippe Arnoux
- Fonction : Auteur
- PersonId : 10058
- IdHAL : philippe-arnoux
- ORCID : 0000-0002-6834-9597
Céline Frochot
- Fonction : Auteur
- PersonId : 17784
- IdHAL : celine-frochot
- ORCID : 0000-0002-7659-3864
- IdRef : 084065583
Résumé
Light‐activated treatments, such as photodynamic therapy (PDT), provide temporal and spatial control over a specific cytotoxic response by exploiting toxicity differences between irradiated and dark conditions. In this work, a novel strategy for developing near infrared (NIR)‐activatable Ru(II) polypyridyl‐based photosensitizers (PSs) was successfully developed through the incorporation of symmetric heptamethine cyanine dyes in the metal complex via a phenanthrimidazole ligand. Owing to their strong absorption in the NIR region, the PSs could be efficiently photoactivated with highly penetrating NIR light (770 nm), leading to high photocytotoxicities towards several cancer cell lines under both normoxic and hypoxic conditions. Notably, our lead PS (Ru‐Cyn‐1), which accumulated in the mitochondria, exhibited a good photocytotoxic activity under challenging low‐oxygen concentration (2% O2) upon NIR light irradiation conditions (770 nm), owing to a combination of types I and II PDT mechanism. The fact that the PS Protoporphyrin IX (PpIX), the metabolite of the clinically approved 5‐ALA PS, was found inactive under the same challenging conditions positions Ru‐Cyn‐1 complex as a promising PDT agent for the treatment of deep‐seated hypoxic tumours.
Format du dépôt | Fichier |
---|---|
Type de dépôt | Article dans une revue |
Titre |
en
Ru(II)‐Cyanine Complexes as Promising Photodynamic Photosensitizers for the Treatment of Hypoxic Tumours with Highly Penetrating 770 nm Near‐Infrared Light
|
Résumé |
en
Light‐activated treatments, such as photodynamic therapy (PDT), provide temporal and spatial control over a specific cytotoxic response by exploiting toxicity differences between irradiated and dark conditions. In this work, a novel strategy for developing near infrared (NIR)‐activatable Ru(II) polypyridyl‐based photosensitizers (PSs) was successfully developed through the incorporation of symmetric heptamethine cyanine dyes in the metal complex via a phenanthrimidazole ligand. Owing to their strong absorption in the NIR region, the PSs could be efficiently photoactivated with highly penetrating NIR light (770 nm), leading to high photocytotoxicities towards several cancer cell lines under both normoxic and hypoxic conditions. Notably, our lead PS (Ru‐Cyn‐1), which accumulated in the mitochondria, exhibited a good photocytotoxic activity under challenging low‐oxygen concentration (2% O2) upon NIR light irradiation conditions (770 nm), owing to a combination of types I and II PDT mechanism. The fact that the PS Protoporphyrin IX (PpIX), the metabolite of the clinically approved 5‐ALA PS, was found inactive under the same challenging conditions positions Ru‐Cyn‐1 complex as a promising PDT agent for the treatment of deep‐seated hypoxic tumours.
|
Auteur(s) |
Albert Gandioso
1
, Eduardo Izquierdo-García
1
, Pierre Mesdom
1
, Philippe Arnoux
2
, Nurikamal Demeubayeva
2
, Pierre Burckel
3
, Bruno Saubaméa
4
, Manel Bosch
5
, Céline Frochot
2
, Vicente Marchán
5
, Gilles Gasser
1
1
ENSCP -
Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL
( 300372 )
- 11, rue Pierre et Marie Curie
75231 Paris Cedex 05
- France
2
LRGP -
Laboratoire Réactions et Génie des Procédés
( 211875 )
- Université de Lorraine - ENSIC, 1 rue de Grandville BP 20451, 54001 Nancy Cedex
- France
3
IPGP (UMR_7154) -
Institut de Physique du Globe de Paris
( 1005035 )
- 1 rue Jussieu, 75238 Paris cedex 05 et Bât. Lamarck A case postale 7011, 75205 Paris CEDEX 13
- France
4
P-MIM - UMS 3612 -
Plates-formes mutualisées du centre de recherche pharmaceutique de Paris
( 1004697 )
- Faculté de pharmacie de Paris - Université Paris Descartes
4 Avenue de l'Observatoire
75006 Paris
- France
5
UB -
Universitat de Barcelona
( 3447 )
- Gran Via de les Corts Catalanes, 585, 08007 Barcelona
- Espagne
|
Vulgarisation |
Non
|
Comité de lecture |
Oui
|
Audience |
Internationale
|
Date de publication électronique |
2023-08-07
|
Date de publication |
2023-11
|
Volume |
29
|
Numéro |
61
|
Page/Identifiant |
e202301742
|
Langue du document |
Anglais
|
Nom de la revue |
|
Projet(s) Européen(s) |
|
Financement |
|
Domaine(s) |
|
Projet(s) ANR |
|
Mots-clés |
en
cyanine, medicinal inorganic chemistry, photodynamic therapy, photosensitizer, ruthenium(II) complexes
|
DOI | 10.1002/chem.202301742 |
Origine :
Fichiers produits par l'(les) auteur(s)
Loading...